戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 the novel anti-angiogenic agent bevacizumab (Avastin).
2 n and that heparin increased VEGF binding to Avastin.
3  of GLV-1h68 and multiple i.p. injections of Avastin.
4 ht be used to expand the clinical utility of Avastin.
5          The recent approval of bevacizumab (Avastin), a humanized anti-vascular endothelial growth f
6 Drug Administration approval of bevacizumab (Avastin), a recombinant humanized anti-vascular endothel
7    Currently, one clinical trial is studying Avastin alone for acute vision-threatening ROP stage 3 i
8             Recent reports detail the use of Avastin alone, and in combination with light amplificati
9 he introduction and approval of bevacizumab (Avastin), an anti-vascular endothelial growth factor ant
10 fic binding to other therapeutic antibodies (Avastin and Rituxan) was observed.
11 (Ozurdex), along with off-label bevacizumab (Avastin) and preservative-free triamcinolone, has signif
12 ons in the therapeutic antibody bevacizumab (Avastin) and the model anti-fluorescein antibody 4-4-20.
13 not to control antibodies such as Herceptin, Avastin, and Arzerra.
14                                 Bevacizumab [Avastin; anti-vascular endothelial growth factor (VEGF)
15 cuss the development and use of bevacizumab (Avastin; anti-vascular endothelial growth factor antibod
16         PURPOSE The AVEREL trial [A Study of Avastin (Bevacizumab) in Combination With Herceptin (Tra
17                                              Avastin (bevacizumab) therapy is a promising anti-vascul
18 oral injection of the VEGF-blocking antibody Avastin (bevacizumab), pharmacologic P2X7 blockade, or P
19                                              Avastin binding to VEGF was dramatically reduced at acid
20 us pemetrexed vs cisplatin; the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS) of cisplatin p
21  inhibited VEGF binding to cells and FN, yet Avastin could still bind to VEGF that was bound to FN, i
22 e possibility that VEGF antagonists, such as Avastin, could inhibit tumor growth by a mechanism invol
23 sing humanized monoclonal antibodies such as Avastin, effectively abrogated the EMT and oncogenesis i
24                             In contrast, the Avastin epitope overlaps minimally with the receptor bin
25      Another clinical trial is investigating Avastin following LASER therapy for recurrent ROP stages
26                                 Bevacizumab (Avastin; Genentech Inc, South San Francisco, CA) 5 mg/kg
27                                 Bevacizumab (Avastin; Genentech Inc, South San Francisco, CA), a reco
28 mmarize the relative effects of bevacizumab (Avastin; Genentech, Inc, South San Francisco, CA) and ra
29                                 Bevacizumab (Avastin; Genentech, South San Francisco, CA) is a recomb
30                                          The Avastin in Glioblastoma trial has shown that patients ne
31 e transitions and treatment effects from the Avastin in Glioblastoma trial, costs and resource use da
32 ls in newly diagnosed glioblastoma: AVAGlio (Avastin in Glioblastoma; NCT00943826), CENTRIC (Cilengit
33 -stromal communication and was equivalent to Avastin in suppressing blood vessel growth in mice harbo
34 omized noninferiority trial Lucentis, Eylea, Avastin in Vein Occlusion (LEAVO), which evaluated intra
35                                 In contrast, Avastin inhibited VEGF binding to cells and FN, yet Avas
36                           In this biosensor, Avastin is used as the specific biorecognition element,
37       Bevacizumab, sold under the brand name Avastin, is a humanized mAb that binds VEGF and blocks i
38  element, and MGO is used as the carrier for Avastin loading.
39 sed data supports early findings, the use of Avastin may be recommended without the need for ablative
40                                              Avastin-mediated VEGF neutralization was capable of sign
41           Furthermore, the advantages of the Avastin-MGO-modified biosensor for VEGF detection are th
42  alcohol dehydrogenase), IgG antibody (e.g., avastin), protein-DNA complexes, and macromolecular asse
43                                 Bevacizumab (Avastin(R)), a monoclonal antibody against vascular endo
44                                 Bevacizumab (Avastin(R)), an anti-angiogenic monoclonal antibody, has
45  at acidic pH was rescued by heparin, as was Avastin's ability to inhibit VEGF binding to cells.
46               In this study, we investigated Avastin's capacity to modulate VEGF165 binding to porcin
47                             We observed that Avastin slightly enhanced VEGF binding to heparin and th
48 endothelial growth factor-directed antibody, Avastin, suppressed angiogenesis in mice but, as expecte
49                               The ability of Avastin to modulate other nonreceptor interactions of VE
50                               The ability of Avastin to prolong survival in a Phase III clinical tria
51                   Interestingly, the reduced Avastin-VEGF binding at acidic pH was rescued by heparin
52                                              Avastin, which only inhibits the tumor-derived human VEG
53                                              Avastin will be especially useful for ROP stage 3 cases